+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Metabolic Disorder Drugs Market Global Briefing 2018

  • ID: 4452386
  • Report
  • January 2018
  • Region: Global
  • 33 pages
  • The Business Research Company
1 of 6

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • MORE
North America was the largest region in the metabolic disorder drugs market in 2016, accounting for around 53% market share. This was mainly due to high prevalence of metabolic syndrome (combination of metabolic diseases including type-2 diabetes) in the USA. Western Europe was the second largest region accounting for around 16% market share. Asia Pacific was the third largest region accounting for around 15% market share.

Metabolic Disorder Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorder drugs sector.

Reasons to Purchase:
  • Fully updated for 2018.
  • Identify growth segments and opportunities.
  • Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
  • Develop strategies based on likely future developments.
  • Gain a global perspective on the development of the market.
Description

Metabolic Disorder Drugs Market Global Briefing 2018 covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the metabolic disorder drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the metabolic disorder drugs market and suggests approaches.

Scope:

Markets Covered: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).
Companies Mentioned: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG
Geographic Scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa
Time Series: Five years historic and forecast.
Data: Market value in $ billions.
Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • MORE
Metabolic Disorder Drugs Market Characteristics
Metabolic Disorder Drugs Market Historic Growth (2013 - 2017)
Metabolic Disorder Drugs Market Forecast Growth (2017 - 2021)
Metabolic Disorder Drugs Market Segmentation
Global Metabolic Disorder Drugs Market, Split by Segments, 2017, $ Billion
Anti-diabetics Drugs
Anti-thyroid drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
Global Metabolic Disorder Drugs Market, Historic and Forecast, Split by Segments, 2013 - 2021
Metabolic Disorder Drugs Market Geography Regional and Country Comparison
Global Metabolic Disorder Drugs Market, Split by Regions, 2017
Global Metabolic Disorder Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Global Metabolic Disorder Drugs Market, Split by Country, 2017
Global Metabolic Disorder Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Metabolic Disorder Drugs Market Competitive Landscape
Sanofi S.A
Novo Nordisk A/S
AstraZeneca Plc
Johnson & Johnson
Merck & Co
Abbott Laboratories Inc
Boehringer Ingelheim GmbH
AbbVie Inc
Takeda Pharmaceticals
Pfizer Inc
Sanofi
Novo Nordisk
AstraZeneca PLC
Metabolic Disorders Drugs Market Key Mergers and Acquisitions
Alexion Acquired Synageva
AstraZeneca Acquired ZS Pharma
Horizon Pharma Plc. Acquired Hyperion Therapeutics, Inc
Horizon Pharma Plc. Acquired Raptor Pharmaceutical Corp
Madrigal Pharmaceuticals Merged With Synta Pharmaceuticals Corp
Metabolic Disorders Drugs Market Trends and Strategies
Development of New Anti-Diabetic Drugs For Type 2 Diabetes
Enzyme Replacement Therapies For the Treatment of Of Rare Metabolic Disorders
Increase in Mergers and Acquisitions
Appendix
NAICS Definitions of Industry Covered in This Report
Definition of Market Covered in This Report
The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism
Abbreviations
Currencies
Research Methodology
Research Inquiries
About the Publisher
Copyright and Disclaimer

List of Figures
Figure 1: Global Metabolic Disorder Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Figure 2: Global Metabolic Disorder Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Figure 3: Global Metabolic Disorder Drugs Market, Split by Segments, 2017, $ Billion
Figure 4: Global Metabolic Disorder Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Figure 5: Global Metabolic Disorder Drugs Market, Split by Region, 2017, $ Billion
Figure 6: Global Metabolic Disorder Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Figure 7: Global Metabolic Disorder Drugs Market, Split by Country, 2017, $ Billion
Figure 8: Global Metabolic Disorder Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Figure 9: Global Metabolic Disorder Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%)

List of Tables
Table 1: Global Metabolic Disorder Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Table 2: Global Metabolic Disorder Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Table 3: Global Metabolic Disorder Drugs Market, Split by Segments, 2017, $ Billion
Table 4: Global Metabolic Disorder Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Table 5: Global Metabolic Disorder Drugs Market, Split by Region, 2016, $ Billion
Table 6: Global Metabolic Disorder Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Table 7: Global Metabolic Disorder Drugs Market, Split by Country, 2016, $ Billion
Table 8: Global Metabolic Disorder Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2012 - 2020
Table 9: Global Metabolic Disorder Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%)
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • MORE
The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics.

North America was the largest region in the metabolic disorder drugs market in 2016, accounting for around 53% market share. This was mainly due to high prevalence of metabolic syndrome (combination of metabolic diseases including type-2 diabetes) in the USA. Western Europe was the second largest region accounting for around 16% market share. Asia Pacific was the third largest region accounting for around 15% market share.

Development of New Anti-Diabetic Drugs for Type 2 Diabetes - Drug manufacturers are developing various anti-diabetic drugs for type-2 diabetes treatment. Type 2 diabetes is a noninsulin-dependent diabetes that affects sugar (glucose) metabolism of the patient by either resisting or restricting the effects of insulin. in July 2017, researchers at the University of California found that Amlexanox, a repurposed asthma drug with anti-inflammatory and anti-allergic properties, can improve blood sugar levels in type 2 diabetic patients. Similarly, in April 2017, scientists from the Central Drug Research Institute (CDRI) in India had found that chalcone, a plant-derived substance, can be used to produce an anti-diabetic drug that can improve insulin sensitivity and reduce blood glucose levels in patients with type-2 diabetes.
Note: Product cover images may vary from those shown
5 of 6
  • Sanofi S.A.
  • Novo Nordisk A/S
  • AstraZeneca Plc.
  • Johnson & Johnson
  • Merck & Co.
  • Abbott Laboratories Inc.
  • Boehringer Ingelheim GmbH
  • AbbVie Inc.
  • Takeda Pharmaceuticals
  • Pfizer Inc.
  • Bayer AG
Note: Product cover images may vary from those shown
6 of 6

Loading
LOADING...

Adroll
adroll